Abstract
Background: Myocardial Fibrosis (MF) is an important physiological change after myocardial infarction (MI). MicroRNA-26b (MiR-26b) has a certain inhibitory effect on pulmonary fibrosis. However, the role of miR-26b in MI-induced MF rats and underlying molecular mechanisms remain unknown.
Methods: Forty male Sprague Dawley (SD) rats weighing 200-250 g were divided into four groups (n=10): Sham group, MF group, MF + negative control (NC) agomir group and MF + miR-26b agomir group. Cardiac fibroblasts were isolated from cardiac tissue. Fibrosis levels were detected by MASSON staining, while the expression of related genes was detected by RT-qPCR, Western blotting and Immunohistochemistry, respectively. TargetScan and dual-luciferase reporter assay were utilized to predict the relationship between miR-26b and high mobility group, AT-hook 2 (HMGA2).
Results: The study found the expression of miR-26b to be down-regulated in the myocardium of MF rats (P<0.01). miR-26b overexpression in vitro significantly reduced the survival rate of cardiac fibroblasts and inhibited the expression of the fibrillar-associated protein (α-SMA alphasmooth muscle actin (α-SMA) and collagen I) (P<0.01). TargetScan indicated that HMGA2 was one of the target genes of miR-26b; dual-luciferase reporter assay further confirmed the targeted regulatory relationship (P<0.01). Moreover, miR-26b overexpression significantly reduced the expression of HMGA2 (P<0.01). Notably, HMGA2 overexpression reversed the inhibitory effect of miR-26b overexpression on cardiac fibroblast viability and the expression of α-SMA and collagen I (P<0.01). Animal experiments further indicated that miR-26b overexpression inhibited MIinduced rat MF by inhibiting the expression of HMGA2 (P<0.05, P<0.01).
Conclusion: In short, these findings indicate that miR-26b targets HMGA2 to ameliorate MI-induced fibrosis by suppression of cardiac fibroblasts activation.
Keywords: Myocardial infarction, myocardial fibrosis, mir-26b, high mobility group, AT-hook 2, cardiac fibroblasts.
[http://dx.doi.org/10.1002/clc.20922] [PMID: 21688276]
[http://dx.doi.org/10.3892/mmr.2016.5163] [PMID: 27109054]
[http://dx.doi.org/10.1139/cjpp-2016-0687] [PMID: 28273426]
[http://dx.doi.org/10.1093/cvr/cvx146] [PMID: 28957531]
[http://dx.doi.org/10.1067/mlc.2000.105971] [PMID: 10779047]
[http://dx.doi.org/10.12659/MSM.908936] [PMID: 30365482]
[http://dx.doi.org/10.1186/1476-4598-12-30] [PMID: 23617834]
[PMID: 31091849]
[http://dx.doi.org/10.2174/157489009788452977] [PMID: 19519553]
[http://dx.doi.org/10.1097/CRD.0000000000000114] [PMID: 27465537]
[http://dx.doi.org/10.1038/nature07511] [PMID: 19043405 ]
[http://dx.doi.org/10.1073/pnas.0805038105] [PMID: 18723672]
[http://dx.doi.org/10.1002/jcp.25341] [PMID: 26873752]
[http://dx.doi.org/10.3892/ijmm.2016.2705] [PMID: 27513632]
[http://dx.doi.org/10.1016/j.bbrc.2016.09.154] [PMID: 27693697]
[http://dx.doi.org/10.18632/aging.102112] [PMID: 31408435]
[http://dx.doi.org/10.1007/s00246-018-2006-5] [PMID: 30315339]
[http://dx.doi.org/10.1136/jim-2016-000092]
[http://dx.doi.org/10.1016/j.jacc.2015.10.063] [PMID: 26796388]
[http://dx.doi.org/10.1371/journal.pone.0075557] [PMID: 24086569]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.094524] [PMID: 22811578]
[http://dx.doi.org/10.1016/j.ijcard.2018.12.077] [PMID: 30679074]
[http://dx.doi.org/10.1016/j.tcm.2014.06.003] [PMID: 25066487]
[http://dx.doi.org/10.1182/blood-2015-11-679431] [PMID: 27081096]
[http://dx.doi.org/10.1038/cddis.2014.207] [PMID: 24853416]
[http://dx.doi.org/10.1038/labinvest.2013.108] [PMID: 24042439]
[http://dx.doi.org/10.1074/jbc.M116.773291] [PMID: 28536261]